| [1] |
Beninato T, Lo Russo G, Garassino MC, et al. Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report[J]. Tumori, 2020, 106(6): NP41-NP45. DOI: 10.1177/0300891620905665.
|
| [2] |
Ng TL, Smith DE, Mushtaq R, et al. ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboembolic events[J]. J Thorac Oncol, 2019, 14(4): 596-605. DOI: 10.1016/j.jtho.2018.12.001.
pmid: 30543838
|
| [3] |
Yang G, Wang J, Yao Y, et al. Peripheral lung squamous carcinoma with ROS1 rearrangement sensitive to crizotinib: a case report[J]. Front Oncol, 2021, 11: 703318. DOI: 10.3389/fonc.2021.703318.
|
| [4] |
Ju L, Han M, Su J, et al. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib[J]. Cancer Chemother Pharmacol, 2018, 82(3): 561-564. DOI: 10.1007/s00280-018-3660-2.
|
| [5] |
梁茂丽, 周亮, 朱蕾, 等. ROS1阳性肺鳞癌1例并文献复习[J]. 医药前沿, 2018, 8(26): 17-18. DOI: 10.3969/j.issn.2095-1752.2018.26.011.
|
| [6] |
Kato M, Shukuya T, Mori K, et al. Cerebral infarction in advanced non-small cell lung cancer: a case control study[J]. BMC Cancer, 2016, 16: 203. DOI: 10.1186/s12885-016-2233-1.
pmid: 26964872
|
| [7] |
Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer: incidence and etiology[J]. Neurology, 2004, 62(11): 2025-2030. DOI: 10.1212/01.wnl.0000129912.56486.2b.
pmid: 15184609
|
| [8] |
Ichinokawa H, Nagasaki Y, Koike Y, et al. Left pneumonectomy for primary lung cancer with Trousseau's syndrome[J]. BMJ Case Rep, 2021, 14(3): e240927. DOI: 10.1136/bcr-2020-240927.
|
| [9] |
程雪娇, 伊然, 董齐, 等. Trousseau综合征的研究进展[J]. 中国临床神经科学, 2019, 27(1): 90-97, 112.
|
| [10] |
Itchins M, Alexander M, John T, et al. Thromboembolism in ROS1 rearranged non-small cell lung cancer[J]. J Thorac Oncol, 2018, 13(10): S684. DOI: 10.1016/j.jtho.2018.08.1104.
|
| [11] |
Chiari R, Ricciuti B, Landi L, et al. ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase Ⅱ, prospective, multicenter, two-arms trial (METROS)[J]. Clin Lung Cancer, 2020, 21(1): 15-20. DOI: 10.1016/j.cllc.2019.06.012.
pmid: 31607443
|
| [12] |
Guo YJ, Chang MH, Chen PL, et al. Predictive value of plasma (D)-dimer levels for cancer-related stroke: a 3-year retrospective study[J]. J Stroke Cerebrovasc Dis, 2014, 23(4): e249-254. DOI: 10.1016/j.jstrokecerebrovasdis.2013.10.022.
|
| [13] |
Kim JM, Jung KH, Park KH, et al. Clinical manifestation of cancer related stroke: retrospective case-control study[J]. J Neurooncol, 2013, 111(3): 295-301. DOI: 10.1007/s11060-012-1011-4.
|
| [14] |
Schwarzbach CJ, Fatar M, Eisele P, et al. DWI lesion patterns in cancer-related stroke—specifying the phenotype[J]. Cerebrovasc Dis Extra, 2015, 5(3): 139-145. DOI: 10.1159/000439549.
|
| [15] |
Zhao J, Zheng J, Kong M, et al. Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell[J]. Oncotarget, 2016, 7(45): 74162-74170. DOI: 10.18632/oncotarget.12364.
pmid: 27708233
|
| [16] |
Lee SE, Lee B, Hong M, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma[J]. Mod Pathol, 2015, 28(4): 468-479. DOI: 10.1038/modpathol.2014.107.
|
| [17] |
Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features[J]. Lung Cancer, 2014, 84(2): 121-126. DOI: 10.1016/j.lungcan.2014.02.007.
pmid: 24629636
|
| [18] |
Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007, 131(6): 1190-1203. DOI: 10.1016/j.cell.2007.11.025.
pmid: 18083107
|
